Pulmicort, Budesonide News

OPKO Health, Inc. today announced that it has acquired exclusive worldwide rights from Teva Pharmaceuticals Industries Ltd.

Teva s proprietary budesonide product is currently marketed in Italy under the trade name Xavin for the treatment of asthma.

Opko Health said Thursday that it has acquired exclusive worldwide rights from Teva Pharmaceuticals Industries Ltd.

AstraZeneca today announced that the US District Court for the District of New Jersey has denied Teva's Motion for Summary Judgment of no infringement in the PULMICORT RESPULES patent litigation.

Newly released results from two previously published studies demonstrated patients receiving the maintenance combination asthma therapy SYMBICORT Inhalation Aerosol achieved bronchodilation, or opening of the ...

Newly released results from two previously published studies demonstrated patients receiving the maintenance combination asthma therapy SYMBICORT Inhalation Aerosol achieved bronchodilation, or opening of the ...

The pivotal role of fixed-dose combinations in asthma management and the increasing use of these combinations in chronic obstructive pulmonary disease , coupled with looming patent expiries for ...

Main Category: Respiratory / Asthma Also Included In: Clinical Trials / Drug Trials Article Date: 16 Aug 2008 A 52-week study examined the long-term safety of the maintenance combination asthma therapy, ...

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.

Asthma is the most common chronic childhood disease, affecting nearly 9 million children in the United States.

Asthma is the most common chronic childhood disease, affecting nearly 9 million children in the United States.

People with milder asthma symptoms tend to fare better in the long-term if they start using inhaled steroids early on, a new study suggests.

AstraZeneca today announced that it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for approval of a new indication for SYMBICORT Inhalation Aerosol for the long-term ...

A new open-label study evaluated patient satisfaction with budesonide/formoterol combination therapy and fluticasone/salmeterol combination therapy, as measured by the Asthma Treatment Satisfaction Measure .1 ...

London, UK, May 19 / MARKET WIRE/ -- FOR IMMEDIATE RELEASE SKYEPHARMA PLC - Q1 2008 INTERIM MANAGEMENT STATEMENT LONDON, UK, 19 May 2008 - SkyePharma PLC today makes its first Interim Management Statement . via Customer Interaction Solutions

“We are pleased with the progress we have made during the first quarter”

MAP Pharmaceuticals, Inc. today announced financial results for the first quarter ended March 31, 2008. via Med Ad News

New guidelines issued by the British Thoracic Society and Scottish Intercollegiate Guidelines Network include for the first time, the practice of prescribing a single combination inhaler for both maintenance ... via MediLexicon

Boards for Health, Physical Conditions Asthma, allergies, and other respiratory ailments Recent discussion: Well I thought I was doing really good when I read the thread on what everyone pays for their ... via Baby Center

“SYMBICORT is a combination maintenance treatment for patients with asthma that works rapidly to help improve lung function by reducing inflammation in the lining of the lung”

AstraZeneca today announced submission of a supplemental New Drug Application to the US Food and Drug Administration to seek approval of a new indication for SYMBICORT Inhalation Aerosol for the treatment of ... via Med Ad News

“This study demonstrated no definitive advantage of repeated doses over a single 2000 mcg dose of nebulized budesonide with regard to speed of onset, the size of response in FEV1, and acute asthma severity score in children within 240 minutes”

In children with moderate to severe asthma exacerbations, a single high dose of nebulized budesonide is as effective as multiple doses using lower amounts, according to Turkish researchers. via Rehab Management